Sonoma Private Wealth LLC Sells 525 Shares of Kenvue Inc. (NYSE:KVUE)

Sonoma Private Wealth LLC trimmed its stake in shares of Kenvue Inc. (NYSE:KVUE) by 3.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,674 shares of the company’s stock after selling 525 shares during the quarter. Sonoma Private Wealth LLC’s holdings in Kenvue were worth $363,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of KVUE. Cornerstone Wealth Group LLC boosted its holdings in shares of Kenvue by 176.2% in the 1st quarter. Cornerstone Wealth Group LLC now owns 350,371 shares of the company’s stock worth $7,519,000 after acquiring an additional 223,537 shares in the last quarter. NBC Securities Inc. boosted its stake in Kenvue by 8.4% in the first quarter. NBC Securities Inc. now owns 11,301 shares of the company’s stock worth $242,000 after purchasing an additional 879 shares in the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Kenvue by 56.2% during the first quarter. Janney Montgomery Scott LLC now owns 1,840,875 shares of the company’s stock worth $39,505,000 after purchasing an additional 662,666 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Kenvue in the first quarter valued at $1,050,000. Finally, Norden Group LLC bought a new position in shares of Kenvue in the first quarter valued at about $1,792,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of NYSE:KVUE remained flat at $21.45 during mid-day trading on Friday. 1,317,445 shares of the company were exchanged, compared to its average volume of 18,074,088. The company has a market cap of $41.07 billion, a price-to-earnings ratio of 27.51, a PEG ratio of 2.76 and a beta of 1.40. The stock has a fifty day moving average of $22.25 and a 200 day moving average of $20.20. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $23.55.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The company had revenue of $4 billion for the quarter, compared to analysts’ expectations of $3.93 billion. During the same period last year, the firm posted $0.32 earnings per share. The business’s quarterly revenue was down .3% compared to the same quarter last year. On average, equities analysts anticipate that Kenvue Inc. will post 1.08 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.82%. The ex-dividend date of this dividend is Wednesday, November 13th. Kenvue’s payout ratio is presently 105.13%.

Analysts Set New Price Targets

A number of equities research analysts have commented on KVUE shares. Jefferies Financial Group began coverage on shares of Kenvue in a report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price objective on the stock. Royal Bank of Canada lowered shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a report on Tuesday, September 24th. Deutsche Bank Aktiengesellschaft upped their price target on Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. JPMorgan Chase & Co. raised their price target on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Finally, Citigroup dropped their price objective on Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $22.20.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.